iShares Ageing Population UCITS ETF USD (Acc) USD is a equity ETF from iShares tracking the Ageing Population index through physical replication. Domiciled in Ireland and launched in 2016, the fund manages about 778 M € and charges a TER of 0.40% — 40 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares Ageing Population UCITS ETF USD (Acc) USD competes with 175 other products in the same class and region (Equity, Global): it ranks 49th by fund size and 72nd by ongoing cost, with a TER of 0.40% against a group median of 0.40%. It has been listed since 2016, 10 years of track record.
On a €10,000 investment the TER costs 40 € a year, against 40 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 5.5% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in USD. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| PharmaEssentia | 0.7% |
| Cytokinetics Inc | 0.6% |
| Robinhood Markets Inc | 0.6% |
| Hims Hers Health Inc | 0.6% |
| Alkermes Plc | 0.6% |
| Protagonist Therapeutics Inc | 0.6% |
| Max Healthcare Institute Ltd | 0.6% |
| Viking Holdings Ltd | 0.6% |
| DaVita HealthCare Partners Inc | 0.6% |
| Borsa Italiana | AGED | EUR |
| XETRA | 2B77 | EUR |
| London Stock Exchange | AGES | GBX |
| London Stock Exchange | AGED | USD |
| SIX Swiss Exchange | AGED | USD |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.